Phase 1 study to assess safety and early efficacy of KMA‑targeting car‑t in multiple myeloma More: KOALA trial opens to enrol patients for first‑in‑human KMCAR T‑cell therapy Source: News
read more
Phase 2 bridge data show consistent outcomes in patients with impaired kidney function More: Pepaxti study supports use in wider myeloma population Source: News
read moreBMS is the latest large pharma company to make a major bet on AI, announcing a sweeping agreement with Anthropic to deploy its AI tool Claude as the “shared intelligence platform” across the drugmaker’s global operations. More: BMS taps Anthropic’s
read moreGilead has broadened its partnership with Korean manufacturer Yuhan, agreeing to a $140 million supply deal for active pharmaceutical ingredients for an undisclosed product. More: Gilead inks another deal with Korean API manufacturer Yuhan, this time worth 0M Source: fierce
read moreAfter some six years at the post, Amgen’s finance chief is telegraphing his exit from the California pharma by early next year. More: Amgen, bidding adieu to CFO, lures Galderma exec with hefty .4M bonus Source: fierce
read moreCG Life has hired Collette “Coco” Douaihy, bringing the former Dentsu International, Evoke and Digitas Health leader on board to head up its creative offering to biopharma companies. More: CG Life appoints Collette Douaihy as chief creative officer as C-suite
read more© 1994 - 2026 B.M. Pharmaceuticals